Gjertsen is Director at KG Jebsen Centre of Myeloid Blood Cancer. He served as co-Director for Centre for Cancer Biomarkers (CCBIO) Norwegian Centre of Excellence, University of Bergen, 2016–2022. In 2010-2018, he developed the phase I clinical trials unit at Haukeland University Hospital. His clinical practice is focused on clinical trials in CML and AML, and several early phase clinical trials in AML has been established with single cell biomarker programs for disease profiling and response evaluation. His laboratory is working on intracellular signal transduction, single cell analysis and immune cell profiling for early response evaluation. In 2024 Gjertsen was awarded a five-year KG Jebsen Centre for Myeloid Blood Cancer, focused on signalling targeted therapy guided by single cell signalling profiles tumor and immune cells. Funding support: Norwegian Cancer Society, the Helse Vest Health Trust, the Research Council of Norway, EU TRANSCAN-3 and ERA PerMed. Dr. Gjertsen is founding member and chair of the Norwegian AML Group and the Nordic AML Group, and is member of the Nordic CML Study Group.

2026

• Coen R. Veenstra; Lok Lam Ngai; Patrycja Gradowska et al. (2026). Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies. (external link)

2025

• Lok Lam Ngai; Tom Reuvekamp; Diana Hanekamp et al. (2025). Different features of acute myeloid leukemia stem cell quantification in intensively treated patients. (external link)
• Gandhar K. Datar; Elmira Khabusheva; Archish Anand et al. (2025). Disparate leukemia mutations converge on nuclear phase-separated condensates. (external link)
• Mariano Sanz; Cecilie Gjerde; Bjørn Tore Gjertsen et al. (2025). Bone Augmentation of Atrophic Alveolar Ridges Using a Synthetic Bone Substitute With Mesenchymal Stem Cells: A Randomized, Controlled Clinical Trial. (external link)
• Stein-Erik Gullaksen; Maria Omsland; Mathias Brevik et al. (2025). CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors. (external link)
• Sonia Gavasso; Jonas Bull Haugsøen; Dimitrios Kleftogiannis et al. (2025). High-dimensional Immune Profiling Following Autologous Hematopoietic Stem Cell Transplantation in Relapsing-Remitting Multiple Sclerosis. (external link)
• Sonja Loges; Michael Heuser; Jörg Chromik et al. (2025). Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial. (external link)
• Titas Gladkauskas; Ileana Cristea; Roya Mehrasa et al. (2025). Temperature as a Key Modulator: Investigating Phosphorylation Patterns of p.Asn666 PDGFRB Variants and Their Role in Downstream Signaling. (external link)

2024

• Benjamin William Caulier; Sandy Joaquina; Pascal Francois Gelebart et al. (2024). CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. (external link)
• Hjalmar Flygt; Stina Söderlund; Johan Richter et al. (2024). Correction to: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial (Leukemia, (2024), 10.1038/s41375-024-02145-6). (external link)
• Dimitrios Kleftogiannis; Sonia Gavasso; Benedicte Sjo Tislevoll et al. (2024). Automated cell type annotation and exploration of single-cell signaling dynamics using mass cytometry. (external link)
• Vincent Cuminetti; Joanna Konieczny; Aurora Bernal Mera et al. (2024). Succinate receptor 1 signaling regulates hematopoiesis via S100/a8 and S100/a9 in health and malignancy. (external link)
• Kari Hemminki; Frantisek Zitricky; Asta Försti et al. (2024). Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century. (external link)
• Åslaug Helland; Eli Sihn Samdal Steinskog; Egil Støre Blix et al. (2024). Hever kvaliteten på behandling av kreft. (external link)
• Hjalmar Flygt; Stina Söderlund; Johan Richter et al. (2024). Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial. (external link)
• Alessandra Venanzi; Valeria Cardinali; Vincenzo Perriello et al. (2024). Starry sky pattern predicts RAS pathway activation in NPM1-mutated acute myeloid leukemia. (external link)
• Kristin Bentung Lygre; Rakel Brendsdal Forthun; Trude Høysæter et al. (2024). Assessment of postoperative circulating tumour DNA to predict early recurrence in patients with stage I–III right-sided colon cancer: prospective observational study. (external link)
• Trung Quang Ha; Vibeke Andresen; Bjarte Skoe Erikstein et al. (2024). Preclinical activity of resazurin in acute myeloid leukaemia. (external link)
• Samuli Eldfors; Joseph Saad; Nemo Ikonen et al. (2024). Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia. (external link)
• Øystein Sefland; Stein-Erik Gullaksen; Maria Omsland et al. (2024). Mass cytometric single cell immune profiles of peripheral blood from acute myeloid leukemia patients in complete remission with measurable residual disease. (external link)
• Alesia A. Khan; Daniel James; Vibeke Andresen et al. (2024). Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations. (external link)

2023

• Brunangelo Falini; Bjørn Tore Gjertsen; Vibeke Andresen (2023). The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML?. (external link)
• Andreas Tvedt Skarstein; Tuyen Hoang; Hallvard Haugen et al. (2023). In vitro Study of STAT3-inhibitors in Drug-Resistant Chronic Myeloid Leukemia (CML). (external link)
• Liv Cecilie Vestrheim Thomsen; Alfred Honore; Bjørn Tore Gjertsen et al. (2023). A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC.. (external link)
• Liv Cecilie Vestrheim Thomsen; Alfred Honore; Lars Anders Rokne Reisæter et al. (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC). (external link)
• Jesse M. Tettero; Yara Buisman; Lok Lam Ngai et al. (2023). Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML. (external link)
• Inge G.P. Geelen; Stein-Erik Gullaksen; Mette M. Ilander et al. (2023). Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. (external link)
• Peter Hokland; Isolda I. Fernández; Sylvie D. Freeman et al. (2023). AML in the elderly—A global view. (external link)
• Liv Cecilie Vestrheim Thomsen; Alfred Honore; Lars Anders Rokne Reisæter et al. (2023). A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. (external link)
• Yngvar Fløisand; Mats Remberger; Iris Bigalke et al. (2023). WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. (external link)
• Liv Cecilie Vestrheim Thomsen; Alfred Honore; Lars Anders Rokne Reisæter et al. (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC). (external link)
• Gianantonio Rosti; Tim H. Brümmendorf; Bjørn Tore Gjertsen et al. (2023). Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study. (external link)
• Lok Lam Ngai; Diana Hanekamp; Fleur Janssen et al. (2023). Prospective validation of the prognostic relevance of CD34⁺CD38^– AML stem cell frequency in the HOVON-SAKK132 trial. (external link)
• Jesse M. Tettero; Lok Lam Ngai; Costa Bachas et al. (2023). Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. (external link)
• Brunangelo Falini; Maria Paola Martelli; Lorenzo Brunetti et al. (2023). The NPM1 mutant defines AML irrespective of blast count. (external link)
• Benedicte Sjo Tislevoll; Monica Hellesøy; Oda Helen Eck Fagerholt et al. (2023). Author Correction: Early response evaluation by single cell signaling profiling in acute myeloid leukemia (Nature Communications, (2023), 14, 1, (115), 10.1038/s41467-022-35624-4). (external link)
• Jad Othman; Manja Meggendorfer; Enrico Tiacci et al. (2023). Overlapping features of therapy-related and de novo NPM1-mutated AML. (external link)
• Benedicte Sjo Tislevoll; Monica Hellesøy; Oda Helen Eck Fagerholt et al. (2023). Early response evaluation by single cell signaling profiling in acute myeloid leukemia. (external link)

2022

• Giulia Pianigiani; Francesca Rocchio; Sara Peruzzi et al. (2022). The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. (external link)
• Dimitrios Kleftogiannis; Benedicte Sjo Tislevoll; Monica Hellesøy et al. (2022). Identifying predictors of survival in patients with leukemia using single-cell mass cytometry and machine learning. (external link)
• Kjetil Tasken; Hege Elisabeth Giercksky Russnes; Eline Aas et al. (2022). A national precision cancer medicine implementation initiative for Norway. (external link)
• Benedicte Sjo Tislevoll; Monica Hellesøy; Oda Helen Eck Fagerholt et al. (2022). Early response evaluation by single cell signaling profiling in acute myeloid leukemia. (external link)
• Jesse M. Tettero; Waleed K. W. Al-Badri; Lok Lam Ngai et al. (2022). Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis. (external link)
• Astrid Bjørke Jenssen; Samih Salah Eldin Mahgoub Mohamed-Ahmed; Esko Kankuri et al. (2022). Administration Methods of Mesenchymal Stem Cells in the Treatment of Burn Wounds. (external link)
• Åslaug Helland; Hege Elisabeth Giercksky Russnes; Gro Live Fagereng et al. (2022). Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway (Journal of Translational Medicine, (2022), 20, 1, (225), 10.1186/s12967-022-03432-5). (external link)
• Åslaug Helland; Hege Elisabeth Giercksky Russnes; Gro Live Fagereng et al. (2022). Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. (external link)
• Jani Huuhtanen; Mette Ilander; Bhagwan Yadav et al. (2022). IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. (external link)

2021

• Robert J. Kreitman; Claire Dearden; Pier Luigi Zinzani et al. (2021). Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. (external link)
• Thierry Jaffredo; Alessandra Balduini; Anna Bigas et al. (2021). The eha research roadmap: normal hematopoiesis. (external link)
• Silje Johansen; Ingvild Jenssen Lægreid; Siw Leiknes Ernstsen et al. (2021). Thrombosis and thrombocytopenia after HPV vaccination. (external link)
• Katerina Bakunina; Hein Putter; Jurjen Versluis et al. (2021). The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. (external link)
• Ellen Færgestad Mosleth; Christian Alexander Vedeler; Kristian Hovde Liland et al. (2021). Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis. (external link)
• Sahba Shafiee; Pascal Francois Gelebart; Mihaela-Lucia Popa et al. (2021). Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line. (external link)
• Jeroen Janssen; Bob Löwenberg; Markus Manz et al. (2021). Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds. (external link)
• Neha Rana; Salwa Suliman; Samih Salah Eldin Mahgoub Mohamed-Ahmed et al. (2021). Systemic monocyte-macrophage response to co-transplanting mesenchymal stromal cells and biphasic calcium phosphate biomaterial for bone regeneration. (external link)
• Bob Löwenberg; Thomas Pabst; Johan Maertens et al. (2021). Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: The HOVON-SAKK-132 trial. (external link)
• Lok Lam Ngai; Connie Y. Ma; Orla Maguire et al. (2021). Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. (external link)
• Shamundeeswari Anandan; Liv Cecilie Vestrheim Thomsen; Stein-Erik Gullaksen et al. (2021). Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. (external link)
• Cecilie Bredrup; Ileana Cristea; Leen Abu Safieh et al. (2021). Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions. (external link)
• Monica Hellesøy; Caroline Benedicte Nitter Engen; Tim Grob et al. (2021). Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. (external link)
• Hjalmar Flygt; Stina Söderlund; Jesper Stentoft et al. (2021). Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study. (external link)
• Neha Rana; Salwa Suliman; Samih Salah Eldin Mahgoub Mohamed-Ahmed et al. (2021). Systemic and local innate immune responses to surgical co-transplantation of mesenchymal stromal cells and biphasic calcium phosphate for bone regeneration. (external link)
• Ingvild Haaland; Sigrun Margrethe Hjelle; Håkon Reikvam et al. (2021). p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. (external link)
• Disha Malani; Kumar Adish Kumar; Oscar Brück et al. (2021). Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. (external link)
• Oddmund Nordgård; Rakel Brendsdal Forthun; Morten Lapin et al. (2021). Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. (external link)
• Caroline Engen; Monica Hellesøy; Tim Grob et al. (2021). FLT3-ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation. (external link)
• Kristine Yttersian Sletta; Oriol Castells Marin; Bjørn Tore Gjertsen (2021). Colony stimulating factor 1 receptor in acute myeloid leukemia. (external link)
• Edvin Tang Gundersen; Jan-Lukas Førde; Benedicte Sjo Tislevoll et al. (2021). Repurposing chlorpromazine for anti-leukaemic therapy by nanoparticle encapsulation. (external link)

2020

• Oda Helen Eck Fagerholt; Monica Hellesøy; Stein-Erik Gullaksen et al. (2020). Single cell detection of the p53 protein by mass cytometry. (external link)
• Katrin Kleinmanns; Katharina Bischof; Shamundeeswari Anandan et al. (2020). CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. (external link)
• Heikki Kuusanmäki; Aino-Maija Leppä; Petri Pölönen et al. (2020). Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. (external link)
• Tormod Karlsen Bjånes; Spiros Kotopoulis; Elsa Thodesen Murvold et al. (2020). Ultrasound‐ and microbubble‐assisted gemcitabine delivery to pancreatic cancer cells. (external link)
• Daniele Mercatelli; Massimo Bortolotti; Vibeke Andresen et al. (2020). Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling. (external link)
• Eirin Alme; Karl Wilhelm Törnroos; Bjørn Tore Gjertsen et al. (2020). Synthesis of N-aryl- and N-alkyl-substituted imidazolium silver complexes: Cytotoxic screening by using human cell lines modelling acute myeloid leukaemia. (external link)
• Caroline Benedicte Nitter Engen; Bjørn Tore Gjertsen; Øystein Bruserud et al. (2020). Exploring the boundaries of precision haemato-oncology : The case of FLT3 length mutated acute myeloid leukaemia. (external link)
• G.J. Ossenkoppele; D.A. Breems; G. Stuessi et al. (2020). Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0). (external link)
• Mahesh Tambe; Ella Karjalainen; Markus Vähä-Koskela et al. (2020). Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. (external link)
• Xiang Wang; Linhong Deng; Bjørn Tore Gjertsen (2020). A microfluidic device for differential capture of heterogeneous rare tumor cells with epithelial and mesenchymal phenotypes. (external link)
• Hans-René Bjørsvik; Bjørn Tore Gjertsen; Vijayaragavan Elumalai (2020). Hit to leads with cytotoxic effect in leukemic cells: Total synthesis intermediates as a molecule treasure chest. (external link)
• Dagim Shiferaw Tadele; Joseph Robertson; Richard Crispin et al. (2020). A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. (external link)
• Muntasir M. Majumder; Aino-Maija Leppä; Monica Hellesøy et al. (2020). Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. (external link)
• Ragnhild Haugse; Anika Langer; Elisa Thodesen Murvold et al. (2020). Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Cells. (external link)
• Therese Bredholt Onyango; Sigrun Margrethe Hjelle; Ingvild Haaland et al. (2020). A comparison of p53 isoform profiles and apoptosis induced by camptothecin or a herbal khat extract (Catha edulis (vahl) forssk. ex endl.) in leukemic cell lines: Exploring cellular responses in therapy development. (external link)
• Maria Omsland; Vibeke Andresen; Stein-Erik Gullaksen et al. (2020). Tyrosine kinase inhibitors and interferon‐α increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines (. (external link)
• G.J. Ossenkoppele; D.A. Breems; G. Stuessi et al. (2020). Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. (external link)
• Andreas Hochhaus; Carlo Gambacorti-Passerini; Camille Abboud et al. (2020). Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. (external link)

2019

• Rakel Brendsdal Forthun; Monica Hellesøy; Andre Sulen et al. (2019). Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. (external link)
• Andrea Gras Navarro; Heidi Espedal; Justin Vareecal Joseph et al. (2019). Pretreatment of glioblastoma with bortezomib potentiates natural killer cell cytotoxicity through TRAIL/DR5 mediated apoptosis and prolongs animal survival. (external link)
• Ragnhild Haugse; Anika Langer; Stein-Erik Gullaksen et al. (2019). Intracellular signaling in key pathways is induced by treatment with ultrasound and microbubbles in a leukemia cell line, but not in healthy peripheral blood mononuclear cells. (external link)
• Katharina Bischof; Stian Knappskog; Sigrun Margrethe Hjelle et al. (2019). Influence of p53 isoform expression on survival in high-grade serous ovarian cancers. (external link)
• Katharina Bischof; Line Bjørge; Bjørn Tore Gjertsen et al. (2019). Rethinking Gynecological High- Grade Serous Carcinoma. Portraying the p53 isoform landscape and development of a new preclinical for optical imaging in xenograft models. (external link)
• Frida Johanne Lundevall; Siv Lise Bedringaas; Karl Wilhelm Törnroos et al. (2019). Synthesis and investigation of Ag-NHC complexes with cytotoxic properties towards cell lines modelling acute myeloid leukemia. (external link)
• Vibeke Andresen; Bjørn Tore Gjertsen (2019). Clinical trials of repurposing medicines in acute myeloid leukemia: Limitations and possibilities in the age of precision therapy. (external link)
• Beibei Zhang; Maria del Pilar Ayuda-Duran; Laure Isabelle Piechaczyk et al. (2019). GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells. (external link)
• Nina Louise Jebsen; Torunn Oveland Apelseth; Hans Kristian Haugland et al. (2019). Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: A case report. (external link)
• Bjørn Tore Gjertsen; Benedicte Sjo Tislevoll; Oda Helen Eck Fagerholt et al. (2019). Early response evaluation in AML using mass cytometry. (external link)
• Mohummad Aminur Rahman; Andrea Gras Navarro; Jorunn Brekke et al. (2019). Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. (external link)
• Rakel Brendsdal Forthun; Randi Hovland; Cornelia Schuster et al. (2019). ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. (external link)
• Anna Kreutzman; Bhagwan Yadav; Tim H. Brümmendorf et al. (2019). Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. (external link)
• Stein-Erik Gullaksen; Lucius Bader; Monica Hellesøy et al. (2019). Titrating complex mass cytometry panels. (external link)
• Ida Sofie Grønningsæter; Hanne Kristin Fredly; Bjørn Tore Gjertsen et al. (2019). Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.. (external link)

2018

• Ina Nepstad; Kimberley Joanne Hatfield; Elise Aasebø et al. (2018). Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. (external link)
• Stein-Erik Gullaksen; Bjørn Tore Gjertsen; Jorunn Kirkeleit et al. (2018). Single cell signalling and immune profiles in chronic myeloid leukaemia. (external link)
• Jorunn Kirkeleit; Trond Riise; Tone Bjørge et al. (2018). Maternal exposure to gasoline and exhaust increases the risk of childhood leukaemia in offspring - a prospective study in the Norwegian Mother and Child Cohort Study. (external link)
• Cecilie Gudveig Gjerde; Kamal Babikeir Eln Mustafa; Sølve Hellem et al. (2018). Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial.. (external link)
• Cornelia Schuster; Gro Gausdal; Bjørn Tore Gjertsen et al. (2018). Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma. (external link)
• Maria Omsland; Cynthia A. Pise-Masison; Dai Fujikawa et al. (2018). Inhibition of tunneling nanotube (TNT) formation and Human T-cell leukemia virus type 1 (HTLV-1) transmission by cytarabine. (external link)
• Håkon Reikvam; Jørn Skavland; Stein-Erik Gullaksen et al. (2018). Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. (external link)
• Katharina Bischof; Stian Knappskog; Ingunn Stefansson et al. (2018). High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. (external link)
• Katarina Mariann Jørgensen; Ellen Færgestad Mosleth; Kristian Hovde Liland et al. (2018). Gene expression response in peripheral blood cells of petroleum workers exposed to sub-ppm benzene levels. (external link)
• Robert J. Kreitman; Claire Dearden; Pier Luigi Zinzani et al. (2018). Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. (external link)
• Marte Karen Brattås; Kyrre Flattun Lilleeng; Randi Hovland et al. (2018). Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. (external link)

2017

• Bob Lowenberg; Thomas Pabst; Johan Maertens et al. (2017). Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. (external link)
• Sieghart Sopper; Satu Mustjoki; Deborah White et al. (2017). Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. (external link)
• Sieghart Sopper; Satu Mustjoki; Bjørn Tore Gjertsen et al. (2017). NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. (external link)
• S Laukkanen; T Grönroos; P Pölönen et al. (2017). In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. (external link)
• Vibeke Andresen; Bjørn Tore Gjertsen (2017). Drug Repurposing for the Treatment of Acute Myeloid Leukemia. (external link)
• Rakel Brendsdal Forthun; Elise Aasebø; Josef Daiel Rasinger et al. (2017). Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. (external link)
• Spiros Kotopoulis; Endre Stigen; Mihaela Lucia Popa et al. (2017). Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. (external link)
• Riikka Karjalainen; Mihaela Lucia Popa; M Liu et al. (2017). Stroma-derived factors stimulate JAK/STAT signaling in AML cells resulring in resistance to BCL2 inhibitor Venetoclax. (external link)
• Mika Kontro; Anil Kumar; Muntasir Mamun Majumder et al. (2017). HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. (external link)
• Misbah Sabir; Monica Hellesøy; Jarno Kivioja et al. (2017). development of novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia. (external link)
• Håkon Reikvam; Randi Hovland; Rakel Brendsdal Forthun et al. (2017). Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. (external link)
• Nina Louise Jebsen; Samantha Scarlett; Bergrun Tinna Magnusdottir et al. (2017). Biomarker Panels and Contemporary Practice in Clinical Trials of Targeted Therapy. (external link)
• Stein-Erik Gullaksen; Jørn Skavland; Sonia Gavasso et al. (2017). Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. (external link)
• Bjørn Tore Gjertsen (2017). Proteomics and single cell immune and signaling profiling of myeloid leukemia. (external link)
• Rakel Brendsdal Forthun; Andre Sulen; Gry Sjøholt et al. (2017). combination of interferon-alpha and valproic acid in acute myeloid leukemia cells in vitro and in vivo. (external link)
• Maria del Pilar Ayuda-Duran; B Zhang; L. Piechaczyck et al. (2017). a precision medicin platform for acute myeloid leukemia to help unraveling the molecular addictions of FLT3-ITD-driven AML. (external link)
• Maria Omsland; Øystein Bruserud; Bjørn Tore Gjertsen et al. (2017). Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). (external link)
• Hanna L.M. Rajala; Mohamed El Missiry; Anniina Ruusila et al. (2017). Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. (external link)
• Riikka Karjalainen; Tea Pemovska; Mihaela Lucia Popa et al. (2017). JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. (external link)

2016

• Noortje Thielen; Johan Richter; Matthias Baldauf et al. (2016). Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. (external link)
• Georg Gjorgji Dimcevski; Spiros Kotopoulis; Tormod Karlsen Bjånes et al. (2016). A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. (external link)
• Caroline Benedicte Nitter Engen; Ehsan Hajjar; Bjørn Tore Gjertsen (2016). Development of personalized molecular therapy for acute myeloid leukemia. (external link)
• Spiros Kotopoulis; Georg Gjorgji Dimcevski; Emmet Mc Cormack et al. (2016). Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: A phase I clinical trial. (external link)
• Andre Sulen; Stein Håkon Låstad Lygre; Sigrun Margrethe Hjelle et al. (2016). Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion. (external link)
• Øystein Helland; Mihaela Lucia Popa; Katharina Bischof et al. (2016). The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. (external link)
• Andre Sulen; Stein-Erik Gullaksen; Lucius Bader et al. (2016). Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. (external link)
• Andre Sulen; Bjørn Tore Gjertsen (2016). Leukocyte p38 and p53 proteins after environmental exposure; variation, associations and applicability. (external link)
• Calum Leitch; Tereza Osdal; Vibeke Andresen et al. (2016). Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. (external link)
• Vibeke Andresen; Bjarte Skoe Erikstein; Herschel Mukherjee et al. (2016). Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. (external link)
• Spiros Kotopoulis; Georg Gjorgji Dimcevski; Emmet McCormack et al. (2016). Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: a phase I clinical trial. (external link)
• Georg Gjorgji Dimcevski; Spiros Kotopoulis; Tormod Karlsen Bjånes et al. (2016). Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. (external link)
• Sonia Gavasso; Stein-Erik Gullaksen; Jørn Skavland et al. (2016). Single-cell proteomics: Potential implications for cancer diagnostics. (external link)
• Henrik Hjorth-Hansen; Jesper Stentoft; Johan Richter et al. (2016). Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. (external link)

2015

• Spiros Kotopoulis; Mihaela Lucia Popa; MJ Safont et al. (2015). Sonoporation using Acoustic Cluster Therapy in combination With chemotherapy transiently reduces tumour volume.. (external link)
• Alexander Harald Sandtorv; Calum Leitch; Siv Lise Bedringaas et al. (2015). 4-alkylated silver-N-heterocyclic carbene (NHC) complexes with cytotoxic effects in leukemia cells. (external link)
• Øystein Bruserud; Håkon Reikvam; Hanne Kristin Fredly et al. (2015). Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. (external link)
• Henrik Hjorth-Hansen; Leif Stenke; Stina Söderlund et al. (2015). Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006). (external link)
• Spiros Kotopoulis; Mihaela Lucia Popa; MJ Safont et al. (2015). Sonoporation using Acoustic Cluster Therapy in combination With chemotherapy transiently reduces tumour volume.. (external link)
• Ola Myklebost; Ragnhild A Lothe; Bjørn Tore Gjertsen et al. (2015). Bør hver kreftpasient bli et eget forskningsprosjekt?. (external link)
• Johannes Landskron; Øystein Helland; Knut Martin Torgersen et al. (2015). Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. (external link)
• Bjørn Tore Gjertsen; Patrick Schöffski (2015). Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. (external link)
• Herschel Mukherjee; Kok-Ping Chan; Vibeke Andresen et al. (2015). Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 mediate the cellular localization of nucleophosmin and its aml-associated mutants. (external link)

2014

• Sonia Gavasso; Ellen Færgestad Mosleth; Tove Helene Marøy et al. (2014). Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. (external link)
• Øystein Helland; Mihaela Lucia Popa; Olav Karsten Vintermyr et al. (2014). First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. (external link)
• Elise Aasebø; Marc Vaudel; Olav Mjaavatten et al. (2014). Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. (external link)
• Spiros Kotopoulis; Georg Gjorgji Dimcevski; Bjørn Tore Gjertsen et al. (2014). Sonoporation: from the lab to human clinical trials. (external link)
• David A. Rizzieri; Norbert Vey; Xavier Thomas et al. (2014). A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. (external link)
• Spiros Kotopoulis; Ragnhild Haugse; Maja Mujic et al. (2014). Evaluation of the effects of clinical diagnostic ultrasound in combination with ultrasound contrast agents on cell stress: Single cell analysis of intracellular phospho-signaling pathways in blood cancer cells and normal blood leukocytes. (external link)
• Spiros Kotopoulis; Anthony Delalande; Mihaela Lucia Popa et al. (2014). Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. (external link)
• Ling Li; Tereza Osdal; Yinway Ho et al. (2014). SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. (external link)
• Vibeke Andresen; Maria Omsland; Bjørn Tore Gjertsen et al. (2014). Cell-to-Cell Communication in Acute Myeloid Leukemia by Tunneling Nanotubes. (external link)
• M Kontro; H Kuusanmäki; S Eldfors et al. (2014). Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. (external link)
• Caroline Benedicte Nitter Engen; Line Wergeland; Jørn Skavland et al. (2014). Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions. (external link)
• Bjørn Tore Gjertsen (2014). Mot en mer spesifikk kreftbehandling? :. (external link)
• Peter Hampson; Keqing Wang; Elisabeth Ersvær et al. (2014). Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukemic compound PEP005 in primary AML cells. (external link)
• Johannes Landskron; Øystein Helland; Knut Martin Torgersen et al. (2014). Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. (external link)
• Ingvild Haaland; Jill Anette Opsahl; Frode Berven et al. (2014). Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. (external link)

2013

• Lars Herfindal; Lene Elisabeth Myhren; Bjørn Tore Gjertsen et al. (2013). Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. (external link)
• Ola Kristoffer Øye; Katarina Mariann Jørgensen; Sigrun Margrethe Hjelle et al. (2013). Gel2DE-A software tool for correlation analysis of 2D gel electrophoresis data. (external link)
• Gro Gausdal; Anita Wergeland; Jørn Skavland et al. (2013). Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. (external link)
• Martine Müller Kloster; Elin Hallan Naderi; Ingvild Haaland et al. (2013). cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases. (external link)
• Øystein Helland; Katharina Bishof; Mihaela Lucia Popa et al. (2013). Histone deacetylase inhibisjon i kombinasjon med platinum i en klinisk relevant ortotopisk musemodel for ovarialcancer. (external link)
• Øystein Helland; Mihaela Lucia Popa; Bjørn Tore Gjertsen et al. (2013). Panobinostat / carboplatin delay postsurgical relapse of ovarian carcinomas in an orthotopic mouse model. (external link)
• Hanne Kristin Fredly; Bjørn Tore Gjertsen; Øystein Bruserud (2013). Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. (external link)
• Therese Bredholt; Elisabeth Ersvær; Bjarte Skoe Erikstein et al. (2013). Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. (external link)
• Håkon Reikvam; Astrid Marta Olsnes Kittang; Guro Kristin Melve et al. (2013). Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?. (external link)
• Vibeke Andresen; Xiang Wang; Sakhila Ghimire et al. (2013). Tunneling nanotube (TNT) formation is independent of p53 expression. (external link)
• Emmet McCormack; Katherine J. Adams; Namir J. Hassan et al. (2013). Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1-and LAGE-1-positive tumors. (external link)
• Bjørn Tore Gjertsen (2013). Phosphoprotein signaling in acute myeloid leukemia. (external link)
• Tea Pemovska; Mika Kontro; Bhagwan Yadav et al. (2013). Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. (external link)
• Håkon Reikvam; Ina Nepstad; Andre Sulen et al. (2013). Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. (external link)
• Hanne Kristin Fredly; Elisabeth Ersvær; Astrid Marta Olsnes Kittang et al. (2013). The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. (external link)
• Elisabeth Silden; Sigrun Margrethe Hjelle; Line Wergeland et al. (2013). Expression of TP53 isoforms p53 beta or p53 gamma enhances chemosensitivity in TP53(null) cell lines. (external link)
• Øystein Helland; P. Mihaela; Bjørn Tore Gjertsen et al. (2013). PANOBINOSTAT / CARBOPLATIN DELAY POSTSURGICAL RELAPSE OF OVARIAN CARCINOMA IN AN ORTHOTOPIC MOUSE MODEL. (external link)
• Satu Mustjoki; Johan Richter; Gisela Barbany et al. (2013). Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. (external link)
• Spiros Kotopoulis; Anthony Delalande; Mihaela Popa et al. (2013). Ultrasound and microbubble enhanced therapy of orthotopic human pancreatic cancer in mice. (external link)
• Emmet McCormack; Maja Mujic; Tereza Osdal et al. (2013). Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. (external link)
• Maja Mujic; Ragnhild Haugse; Spiros Kotopoulis et al. (2013). Ultrasound combined with microbubbles modulates signal transduction pathways in blood cells. (external link)
• Georg Gjorgji Dimcevski; Spiros Kotopoulis; Dag Hoem et al. (2013). Ultrasound-assisted treatment of an inoperable pancreatic cancer. (external link)
• Emmet McCormack; Elisabeth Silden; Richard M. West et al. (2013). Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. (external link)
• Caroline Benedicte Nitter Engen; Line Wergeland; Bjørn Tore Gjertsen (2013). Målrettet behandling av akutt myelogen leukemi - hemmere mot FLT3 og andre kinaser viser vei. (external link)

2012

• Maja Mujic; Spiros Kotopoulis; Anthony Delalande et al. (2012). Flow cytometic characterization and sorting of ultrasound contrast agents. (external link)
• Øystein Helland; Mihaela Lucia Popa; Olav Karsten Vintermyr et al. (2012). Establishment of a bioluminescence orthotopic mouse model of ovarian carcinoma: Analysis of tumor growth and response to therapy. (external link)
• Nina Ånensen; Sigrun Margrethe Hjelle; Belle Werner Van et al. (2012). Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. (external link)
• Sonia Gavasso; Tove Helene Marøy; Ellen Færgestad Mosleth et al. (2012). Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. (external link)
• Stein-Erik Uriarte Gullaksen; Alexandre Micoulet; Bjørn Tore Gjertsen (2012). Deformation of acute myeloid leukaemia cells in micro-constriction array; a novel tool to study cell stress signalling. (external link)
• Galina Tsykunova; Håkon Reikvam; Aymen B Ahmed et al. (2012). Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia?. (external link)
• Emmet Martin McCormack; Ingvild Haaland; Gurid Venås et al. (2012). Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. (external link)
• Eystein Oveland; Line Wergeland; Randi Hovland et al. (2012). Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. (external link)
• Sigrun Margrethe Hjelle; Andre Sulen; Ola Kristoffer Øye et al. (2012). Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. (external link)
• Håkon Reikvam; Kimberley Joanne Hatfield; Elisabeth Ersvær et al. (2012). Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. (external link)
• Roger Bjugn; Bjørn Tore Gjertsen (2012). Humane celler og helseforskningsloven. (external link)
• Bjørn Tore Gjertsen; Helge Wiig (2012). Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid. (external link)
• Philip Hallenborg; Søren Feddersen; Sarah Francoz et al. (2012). Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. (external link)
• Francis Giles; François-Xavier Mahon; Bjørn Tore Gjertsen et al. (2012). Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. (external link)
• David A. Rizzieri; Norbert Vey; Xavier Thomas et al. (2012). A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. (external link)
• Hanne Kristin Fredly; Håkon Reikvam; Bjørn Tore Gjertsen et al. (2012). Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. (external link)
• Rakel Brendsdal Forthun; Tanima Sengupta; Hanne Kim Skjeldam et al. (2012). Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. (external link)
• Anthony Delalande; Spiros Kotopoulis; Chantal Pichon et al. (2012). Microbubbles and cell interactions. (external link)
• Ola Kristoffer Øye; Dag Magne Ulvang; Katarina Mariann Jørgensen et al. (2012). Volume visualization for exploration of population trends in two-dimensional gel electrophoresis protein data. (external link)
• Sonia Gavasso; Bjørn Tore Gjertsen; Endre Anderssen et al. (2012). Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. (external link)

2011

• Hanne Kristin Fredly; Elisabeth Ersvær; Bjørn Tore Gjertsen et al. (2011). Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. (external link)
• Katarina Mariann Jørgensen; Sigrun Margrethe Hjelle; Ola Kristoffer Øye et al. (2011). Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukemia. (external link)
• Bjørn Tore Gjertsen (2011). Stratification of pediatric acute myeloid leukemia through cancer cell gene-expression profiling. (external link)
• Jørn Skavland; Katarina Mariann Jørgensen; Kenan Hadziavdic et al. (2011). Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. (external link)
• Crina Elena Tiron; Christine Gjerdrum; Torill Høiby et al. (2011). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. (external link)

2010

• Kimberley Joanne Hatfield; Siv Lise Bedringaas; Anita Ryningen et al. (2010). Hypoxia increases HIF-1 alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. (external link)
• Christine Gjerdrum; Crina Elena Tiron; Torill Høiby et al. (2010). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. (external link)
• Kimberley Joanne Hatfield; Siv Lise Bedringaas; Bjørn Tore Gjertsen et al. (2010). OXYGEN LEVELS INFLUENCE THE CYTOKINE RELEASE PROFILE OF AML CELLS. (external link)
• Emmet Martin McCormack; Jørn Skavland; Maja Mujic et al. (2010). Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia. (external link)
• Hanne Kristin Fredly; Camilla I. Stapnes Bjørnsen; Bjørn Tore Gjertsen et al. (2010). Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - a report of five cases. (external link)
• Bjarte Skoe Erikstein; Emmet Martin McCormack; Karl Johan Tronstad et al. (2010). Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. (external link)
• Elisabeth Ersvær; Knut Liseth; Jørn Skavland et al. (2010). Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. (external link)
• Bjarte Skoe Erikstein; Hanne Hagland; Julie Nikolaisen et al. (2010). Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairment. (external link)
• Sigrun Margrethe Hjelle; Rakel Brendsdal Forthun; Ingvild Haaland et al. (2010). Clinical proteomics of myeloid leukemia. (external link)
• Elvira Semaeva; Olav Tenstad; Jørn Skavland et al. (2010). Access to the spleen microenvironment through lymph shows local cytokine production, increased cell flux, and altered signaling of immune cells during lipopolysaccharide-induced acute inflammation. (external link)
• Jørn Skavland; Kenan Hadziavdic; Inge Jonassen et al. (2010). Combined epigenetic and signal transduction therapy modulate specific signal transduction patterns in acute myeloid leukemia. (external link)

2009

• Astrid Marta Olsnes; Elisabeth Ersvær; Anita Ryningen et al. (2009). The protein kinase C agonist PEP005 increases NF-kB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. (external link)
• Anne Margrete Øyan; Nina Ånensen; Trond Hellem Bø et al. (2009). Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. (external link)
• Bjørn Tore Gjertsen (2009). Er høyt hemoglobinnivå farlig?. (external link)
• Kimberley Joanne Hatfield; Anne Margrete Øyan; Elisabeth Ersvær et al. (2009). Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. (external link)
• Thoralf Christoffersen; Tormod K. Guren; Karen-Lise Garm Spindler et al. (2009). Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. (external link)
• Håkon Reikvam; Astrid Marta Olsnes; Bjørn Tore Gjertsen et al. (2009). Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. (external link)
• Camilla I Stapnes; Bjørn Tore Gjertsen; Håkon Reikvam et al. (2009). Targeted therapy in acute myeloid leukaemia: current status and future directions. (external link)
• Kimberley Joanne Hatfield; Anne Margrete Øyan; Elisabeth Ersvær et al. (2009). Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. (external link)
• Ochiba Mohammed Lukandu; Therese Bredholt; Evelyn Neppelberg et al. (2009). Early loss of mitochondrial inner transmembrane potential in khat-induced cell death of primary normal human oral cells. (external link)
• Matthias Hofmann; Emmet Martin McCormack; Maja Mujic et al. (2009). Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumour model. (external link)
• Jian Wang; Oleg Tsinkalovsky; P Zhao et al. (2009). TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS. (external link)
• Eystein Oveland; Bjørn Tore Gjertsen; Line Wergeland et al. (2009). Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. (external link)
• Therese Bredholt; Elisabeth Anne Okumu Dimba; Hanne Hagland et al. (2009). Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. (external link)
• Thoralf Christoffersen; Bjørn Tore Gjertsen; Olav Engebråten et al. (2009). Signalhemmere. (external link)
• Anita Ryningen; Camilla I Stapnes; Philippe Lassalle et al. (2009). A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. (external link)

2008

• Emmet Martin McCormack; Øystein Bruserud; Bjørn Tore Gjertsen (2008). Review: genetic models of acute myeloid leukaemia. (external link)
• Bjørn Tore Gjertsen; Emmet Martin McCormack (2008). Erythropoietin a safe bet in haemorrhagic shock?. (external link)
• Gro Gausdal; Bjørn Tore Gjertsen; Emmet Martin McCormack et al. (2008). Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. (external link)
• Bjørn Tore Gjertsen; James Lorens (2008). Comprehensive Analysis of Gene Function: RNA interference and Chemical Genomics. (external link)
• Øystein Bruserud; Elisabeth Ersvær; Astrid Marta Olsnes et al. (2008). Anticancer Immunotherapy in Combination with Proapoptotic Therapy. (external link)
• Anita Ryningen; Camilla I Stapnes; Kristin Paulsen et al. (2008). In vivo biological effects of ATRA in the treatment of AML. (external link)
• Kimberley Joanne Hatfield; Randi Hovland; Anne Margrete Øyan et al. (2008). Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. (external link)
• Ochiba Mohammed Lukandu; Daniela Elena Costea; Elisabeth Anne Okumu Dimba et al. (2008). Khat induces G1-phase arrest and increased expression of stress-sensitive p53 and p16 proteins in normal human oral keratinocytes and fibroblasts. (external link)
• Emmet Martin McCormack; Ingvild Haaland; Gurid Venås et al. (2008). Evaluation of combinational therapy of MDM2-antagonist nutlin-3 and HDAC-inhibitor valproic acid in acute myeloid leukemia in vitro and in vivo. (external link)
• Sonia Gavasso; Jørn Skavland; Bjørn Tore Gjertsen et al. (2008). Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. (external link)
• Line Wergeland; Eystein Oveland; Gry Sjøholt et al. (2008). FLT3 internal tandem duplication involving its libiquitin dependent endocytosis motif suspend modulation by HDM2 and are associated with inferior survival in AML. (external link)
• Jorunn Kirkeleit; Trond Riise; Bjørn Tore Gjertsen et al. (2008). Effects of benzene on human hematopoiesis. (external link)

2007

• Nina Ånensen; Anne Margrete Øyan; Sjur Huseby et al. (2007). Early gene expression of acute myeloid leukemia in response to chemotherapy. (external link)
• Bjarte Skoe Erikstein; Karl Johan Tronstad; Emmet Martin McCormack et al. (2007). Synergistic anti-leukemic effect of protein kinase a activator and PPAR7agonist is independent of Bcl-2 status. (external link)
• Francesco Parlati; Monette Aujay; Siv Lise Bedringaas et al. (2007). Anti-tumor activity of immunoproteasome selective inhibitors. (external link)
• Emmet Martin McCormack; Alexandre Belankov; Maja Mujic et al. (2007). Discrimination and quantification of spectrally similar near-infrared probes by time-domain (TD) optical imaging in acute myeloid leukemia mouse models. (external link)
• Line Wergeland; Eystein Oveland; Gry Sjøholt et al. (2007). Flt3 mutations in proximity to an ubiquitin dependent endocytosis motif suspend its Hdm2 modulation. (external link)
• Anne Margrete Øyan; Nina Ånensen; Trond Hellem Bø et al. (2007). Early gene expression signature of chemotherapy treated acute myeloid leukemia in vivo. (external link)
• Anne Margrete Øyan; Trond Hellem Bø; Inge Jonassen et al. (2007). Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. (external link)
• Jonathan C. Irish; Nina Ånensen; Randi Hovland et al. (2007). Flt3 Y591 duplication and Bc1-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. (external link)
• Hanne Hagland; Julie Nikolaisen; Linn Iren Hodneland et al. (2007). Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. (external link)
• Elisabeth Ersvær; Peter Hampson; Kimberley Joanne Hatfield et al. (2007). T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. (external link)
• Camilla I Stapnes; Anne Paulus Døskeland; Kimberley Joanne Hatfield et al. (2007). The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. (external link)
• Camilla I Stapnes; Anita Ryningen; Kimberley Joanne Hatfield et al. (2007). Functional characteristics and gene expression profiles of primary acute myeloid leukamia cells indentify patient subgroups that differ susceptibility to histone deactylase inhibitors. (external link)
• Camilla I Stapnes; Anita Ryningen; Kimberley Joanne Hatfield et al. (2007). Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. (external link)
• Tien-Sheng Huang; Line Merethe Myklebust; Endre Kjærland et al. (2007). LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. (external link)
• Line Wergeland; Gry Sjøholt; Ingvild Haaland et al. (2007). Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. (external link)
• Emmet Martin McCormack; David Robert Micklem; Lars Erik Pindard et al. (2007). In vivo optical Imaging of acute myeloid leukemia by green fluorescent protein: Time-domain autofluorescence decoupling, fluorophore quantification, and localization. (external link)
• Camilla I Stapnes; Anita Ryningen; Kimberley Joanne Hatfield et al. (2007). Linking susceptibility to histone deactylase inhibitors and basal gene expression profiles in acute myeloid leukaemia. (external link)
• Elisabeth Ersvær; Jian-Ying Zhang; Emmet Martin McCormack et al. (2007). Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. (external link)
• Øystein Bruserud; Camilla I Stapnes; Elisabeth Ersvær et al. (2007). Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. (external link)
• Elisabeth Ersvær; Peter Hampson; Øystein Wendelbo et al. (2007). Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. (external link)
• Bjørn Tore Gjertsen; Therese Bredholt; Nina Ånensen et al. (2007). Bcl-2 antisense in the treatment of human malignancies: A delusion in targeted therapy. (external link)
• Emmet Martin McCormack; Alexandre Belankov; Maja Mujic et al. (2007). Discrimination and Quantification of Spectrally Similar Near-Infrared Probes by Time-Domain (TD) Optical Imaging in AML models. (external link)
• Line Wergeland; Eystein Oveland; Gry Sjøholt et al. (2007). Flt3 Mutations in Proximity to an Ubiquitin Dependent Endocytosis Motif Suspend Its Hdm2 Modulation. (external link)
• Maja Mujic; Emmet Martin McCormack; Anita Ryningen et al. (2007). Development and evaluation of labeled antibodies as optical contrast reagents in acute myeloid leukemia (AML). (external link)
• F Parlati; M Aujay; Siv Lise Bedringaas et al. (2007). Anti-Tumor Activity of Immunoproteasome Selective Inhibitors. (external link)
• Gurid Venaas; Emmet Martin McCormack; Ingvild Haaland et al. (2007). In vivo optical imaging of p53 specific targeted therapy in Acute Myeloid Leukaemia. (external link)
• Elisabeth Silden; Emmet Martin McCormack; David Robert Micklem et al. (2007). Development of a near infrared reporter system for in vivo imaging. (external link)
• Bjørn Tore Gjertsen (2007). Early protein and gene modulation in response to induction chemotherapy of acute myeloid leukemia. (external link)
• Bjørn Tore Gjertsen (2007). Early Protein and Gene Modulation in Response to Induction Chemotherapy of Acute Myeloid Leukemia. (external link)
• Elisabeth Ersvær; Øystein Bruserud; Bjørn Tore Gjertsen (2007). Immunological aspects of acute myelogenous leukemia. (external link)
• Gro Gausdal; Bjørn Tore Gjertsen; Stein Ove Doskeland (2007). New lessons from an “old” drug: A proteomic study of anthracycline-induced apoptosis in acute myelogenous leukemia. (external link)
• Line Wergeland; Bjørn Tore Gjertsen; Øystein Bruserud (2007). Flt3 receptor tyrosine kinase in AML and its modulation of the p53/Hdm2/Bcl-2 pathway. (external link)
• Elisabeth Ersvær; Jørn Skavland; Elling Ulvestad et al. (2007). Effects of interferon gamma on native human acute myelogenous leukaemia cells. (external link)
• Øystein Bruserud; Anita Ryningen; Astrid Marta Olsnes et al. (2007). Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. (external link)
• Kjell Petersen; Anne Margrete Øyan; Kari Rostad et al. (2007). Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. (external link)

2006

• Anne Margrete Øyan; Trond Hellem Bø; Inge Jonassen et al. (2006). cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. (external link)
• Nina Ånensen; Anne Margrete Øyan; Jean-Christophe Bourdon et al. (2006). A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. (external link)
• Werner Van Belle; Nina Ånensen; Ingvild Haaland et al. (2006). Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. (external link)
• Nina Ånensen; Jørn Skavland; Camilla I Stapnes et al. (2006). Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report. (external link)
• Eystein Oveland; Kari Espolin Fladmark; Line Wergeland et al. (2006). Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. (external link)
• Anne Margrete Øyan; Nina Ånensen; Trond Hellem Bø et al. (2006). The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. (external link)
• Øystein Bruserud; Camilla I Stapnes; Karl Johan Tronstad et al. (2006). Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. (external link)
• Øystein Bruserud; Emmet Martin McCormack; Bjørn Tore Gjertsen (2006). Immunotherapy in chronic lymphocytic leukemia. (external link)
• Anne Margrete Øyan; Nina Ånensen; Trond Hellem Bø et al. (2006). The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. (external link)

See a complete overview of publications in NVA.